Physician profile
Pierre R Arty
NPI 1912983222
$6,235.42
in general payments reported to CMS, 2019-2025
16 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $418 · 2021: $747 · 2022: $1,133 · 2023: $1,126 · 2024: $1,034 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,145 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.75 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,340.80 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,089.58 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,033.95 | 2019-2023 | Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,022.15 | 2019-2024 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $685.43 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $293.27 | 2022-2023 | |
| Lundbeck LLC | $168.82 | 2020-2024 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $135.62 | 2025 | Cobenfy |
| Indivior INC. | $133.58 | 2019-2021 | |
| Viiv Healthcare Company | $116.96 | 2020-2023 | Rukobia |
| Sunovion Pharmaceuticals INC. | $73.86 | 2019 | |
| Abbvie INC. | $46.53 | 2023-2025 | Vraylar |
| Gilead Sciences, INC. | $30.45 | 2024 | Descovy |
| Janssen Biotech, INC. | $24.64 | 2021 | |
| Corium, LLC | $24.03 | 2023 | Azstarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $15.75 | 2023 | Serostim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Arty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.